Pipeline

 

 

Pipeline

Discovery
New bacterial persistent strains
Set up screening platform
Opérational anti persister screening platform

Anti-persisters screening platform (Operational)

2019
2020
2021
2021
Discovery
Lead Optimisation
Preclinical
Phase I
Phase II
Phase III

NAIAP-OL20-01

2020
2021
2022
2023
2024

MIAMI-Ol20-11

2021
2023
2024
2025
2026

Program

Platform to screen for new molecules against dormant bacteria

In order to have the best first in class molecule to target dormant (persistent) bacteria we developed a proprietary screening platform to test and modify molecules.

NAIAP Program

A collaboration with the university of Rennes 1 in Pr. Felden’s Team (Bacterial Regulatory RNAs & Medicine), we developed news molecules that have the unique ability to eliminate pathogenic resistant bacteria. Moreover, these original molecules are able to eliminate the persisters (dormant bacteria) that are responsible of infectious relapses by targeting a specific feature of these bacteria. Based on these properties several molecules were designed and an original mechanism of action was discovered. We are now modifying the lead candidate OL20-01 on a proprietary platform, the only one able to screen persistent bacteria, in order to find the best in class molecule to cure patients.

MIAMI Program

After 20 years of research development and commercialization of products to fight against antibiotic resistance, the Olmix group has found and licensed a new molecule discovered in algae. This molecule has the property of boosting the immune system in immunodepressed preclinical models and thus could benefit to the patient to avoid nosocomial diseases. The molecule is being isolated, characterized and is now being processed toward preclinical development.